W
aldenström
’
s
macroglobulinemia
–
a
review
R
ev
A
ssoc
M
ed
B
ras
2014; 60(5):490-499
499
37.
Moyner K, Sletten K, Husby G, Natvig JB. An unusually large (83 amino
acid residues) amyloid fibril protein AA from a patient with Waldenström’s
macroglobulinaemia and amyloidosis. Scand J Immunol. 1980;11:549-54.
38.
Shah IA, Netto D, Ashfaq R, Krieger C. Waldenström’s macroglobulinemia
associated with generalized AA-amyloidosis. Int J Surg Pathol. 1993;1:123-7.
39. Gardyn J, Schwartz A, Gal R, Lewinski U, Kristt D, AM. C. Waldenström’s
macroglobulinemia associated with AA amyloidosis. Int J Hematol. 2001
74:76-8.
40.
Hunter ZR, Manning RJ, Hanzis C, Ciccarelli BT, Ioakimidis L, Patterson
CJ, et al. IgA and IgG hypogammaglobulinemia in Waldenstrom’s
macroglobulinemia. Haematologica. 2010;95:470-5.
41.
Singh A, Eckardt KU, Zimmermann A, Götz KH, Hamann M, Ratcliffe PJ,
et al. Increased plasma viscosity as a reason for inappropriate erythropoietin
formation. J Clin Invest. 1993;91:251-6.
42.
Roux S, Fermand JP, Brechignac S, Mariette X, Kahn MF, Brouet JC. Tumoral
joint involvement in multiple myeloma and Waldenström’s
macroglobulinemia -report of 4 cases. J Rheumatol. 1996;23:2175-8.
43.
Kaila VL, El-Newihi HM, Dreiling BJ, Lynch CA, Mihas AA. Waldenström’s
macroglobulinemia of the stomach presenting with upper gastrointestinal
hemorrhage. Gastrointest Endosc. 1996;44:73-5.
44. Yasui O, Tukamoto F, Sasaki N, Saito T, Yagisawa H, Uno A, et al. Malignant
lymphoma of the transverse colon associated with macroglobulinemia. Am
J Gastroenterol. 1997;92:2299-301.
45.
Rosenthal JA, Curran WJ, Schuster SJ. Waldenström’s macroglobulinemia
resulting from localized gastric lymphoplasmacytoid lymphoma. Am J
Hematol. 1998;58:244-5.
46.
Recine MA, Perez MT, Cabello-Inchausti B, Lilenbaum RC, Robinson MJ.
Extranodal lymphoplasmacytoid lymphoma (immunocytoma) presenting
as small intestinal obstruction. Arch Pathol Lab Med. 2001;125:677-9.
47.
Rausch PG, Herion JC. Pulmonary manifestations of Waldenstrom
macroglobulinemia. Am J Hematol. 1980;9:201-9.
48.
Fadil A, Taylor DE. The lung and Waldenstrom’s macroglobulinemia. South
Med J. 1998;91:681-5.
49. Veltman GA, van Veen S, Kluin-Nelemans JC, Bruijn JA, van Es LA. Renal
disease in Waldenström’s macroglobulinaemia. Nephrol Dial Transplant.
1997;12:1256-9.
50.
Mascaro JM, Montserrat E, Estrach T, Feliu E, Ferrando J, Castel T, et al.
Specific cutaneous manifestations of Waldenström’s macroglobulinemia.
A report of two cases. Br J Dermatol. 1982;106:17-22.
51. Orellana J, Friedman AH. Ocular manifestations of multiple myeloma,
Waldenström’s macroglobulinemia and benign monoclonal gammopathy.
Surv Ophthalmol. 1981;26:157-69.
52.
Ettl AR, Birbamer GG, Philipp W. Orbital involvement in Waldenström’s
macroglobulinemia: ultrasound, computed tomography and magnetic
resonance findings. Ophthalmologica. 1992;205:40-5.
53. Civit T, Coulbois S, Baylac F, Taillandier L, Auque J. Waldenström’s
macroglobulinemia and cerebral lymphoplasmocytic proliferation: Bing and
Neel syndrome. Apropos of a new case. Neurochirurgie. 1997;43:245-9.
54.
Lin P, Mansoor A, Bueso-Ramos C, Hao S, Lai R, Medeiros LJ. Diffuse large
B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/
Waldenstrom macroglobulinemia - clinicopathologic features of 12 Cases.
Am J Clin Pathol. 2003;120:246-53.
55.
Feiner HD, Rizk CC, Finfer MD, Bannan M, Gottesman SR, Chuba JV, et al.
IgM monoclonal gammopathy/Waldenström’s macroglobulinemia: a
morphological and immunophenotypic study of the bone marrow. Mod
Pathol. 1990;3:348-56.
56.
San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sánchez-Guijo F, Sánchez
ML, et al. Immunophenotypic analysis of Waldenstrom’s macroglobulinemia.
Semin Oncol. 2003;30:187-95.
57. Pangalis G, Kyrtsonis M-C, Kontopidou F, Siakantaris M, Dimopoulou M,
Vassilakopoulos T, et al. Differential diagnosis of Waldenström’s
macroglobulinemia and other B-Cell disorders. Clin Lymphoma. 2005;5:235-40.
58.
Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et
al. A long-term study of prognosis in monoclonal gammopathy of
undetermined significance. N Engl J Med. 2002;346:564-9.
59.
Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR,
et al. Long-term follow-up of IgMmonoclonal gammopathy of undetermined
significance. Blood. 2003;102:3759-64.
60.
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J,
et al. International prognostic scoring system for Waldenstrom
macroglobulinemia. Blood. 2009;113:4163-70.
61.
Kastritis E, Kyrtsonis MC, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis
P, et al. Validation of the International Prognostic Scoring System (IPSS)
for Waldenstrom’s macroglobulinemia (WM) and the importance of serum
lactate dehydrogenase (LDH). Leuk Res. 2010;34:1340-3.
62. TreonSP.HowItreatWaldenstrommacroglobulinemia.Blood.2009;114:2375-85.
63. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, LeBlond V,
et al. Update on treatment recommendations from the Fourth International
Workshop onWaldenström’s macroglobulinemia. J ClinOncol. 2009;27:120-6.
64. Vijay A, Gertz M. Current treatment options for Waldenström
macroglobulinemia. Clin Lymphoma. 2008;8:219-29.
65.
Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C,
Kokkinis G, et al. Primary treatment of Waldenström macroglobulinemia
with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol.
2007;25:3344-9.
66. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The
clinical application of monoclonal antibodies in chronic lymphocytic
leukemia. Blood. 2010;116:3705-14.
67.
Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of
action and resistance. Oncogene. 2003;22: 7359-68.
68. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E,
et al. Polymorphisms in Fc’RIIIA (CD16) receptor expression are associated
with clinical response to rituximab in Waldenström’s macroglobulinemia.
J Clin Oncol. 2005;23:474-81.
69. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, et al. Initial
immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed
with Waldenstrom macroglobulinemia. Cancer. 2004;101:2593-8.
70.
Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki
V, et al. Treatment of Waldenström’s macroglobulinemia with rituximab. J
Clin Oncol. 2002;20:2327-33.
71. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC.
Paradoxical increases in serum IgM and viscosity levels following rituximab
in Waldenstrom’s macroglobulinemia. Ann Oncol. 2004;15:1481-3.
72.
Issa GC, Ghobrial IM, Roccaro AM. Novel agents in Waldenström
macroglobulinemia. Clin Invest (Lond). 2011;1:815-24.
73. Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, et al.
Response assessment in Waldenstrom macroglobulinaemia: update from
the 6
th
International Workshop. Br J Haematol. 2013;160:171-6.
74. Ciccarelli BT, Yang G, Hatjiharissi E, Ioakimidis L, Patterson CJ, Manning RJ,
et al. Soluble CD27 is a faithful marker of disease burden and is unaffected by
the rituximab-induced IgMflare, as well as by plasmapheresis, in patients with
Waldenstrom’s macroglobulinemia. Clin Lymphoma. 2009;09:56 AM-8.
75.
Itzykson R, Le Garff-Tavernier M, Katsahian S, Diemert MC, Musset L,
Leblond V. Serum-free light chain elevation is associated with a shorter time
to treatment in Waldenstrom’s macroglobulinemia. Haematologica.
2008;93:793-4.
76.
Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol.
2007;138:700-20.